Acadia Pharma (ACAD): No NUPLAZID Data Until Mid 2017 - HC Wainwright

H.C. Wainwright analyst, Andrew Fein, reiterated his Buy on Acadia Pharmaceuticals (NASDAQ: ACAD) after meeting with management but noted that he expects management to wait to provide metrics on how the launch is progressing toward the middle of 2017. This should lead to a tightening of consensus for 2H17.

No change to the price target of $60.00

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $34.98 yesterday.

You May Also Be Interested In

• Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
• Equity Residential (EQR) PT Raised to $70 at Evercore ISI
• Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'